Pfizer Moves To Toss More Cases From Bextra MDL

Law360, New York (September 17, 2007, 12:00 AM EDT) -- Drug maker Pfizer Inc. has moved to throw out almost two dozen cases from the multidistrict litigation over its anti-inflammatory drugs Bextra and Celebrex, arguing the plaintiffs involved failed to comply with an “essential” court order.

In a motion for dismissal filed Friday in the U.S. District Court for the Northern District of California, the pharmaceutical company accused the plaintiffs of hampering progress in the MDL by ignoring case management directives that serve as the “engine that drives disposition on the merits.”

“The litigation cannot run...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.